文献速递临床试验与 GCP

特瑞普利单抗联合治疗不联合同期顺铂治疗鼻咽癌:DIAMOND随机临床试验

Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

DIAMOND研究为开放标签、多中心、随机3期试验,2021年8月至2022年7月在中国13家医院纳入532例局部晚期鼻咽癌患者,随机分至标准治疗组(特瑞普利单抗+吉西他滨-顺铂诱导化疗+同期顺铂放疗)或不联合同期顺铂组(相同方案但省略同期顺铂)。中位随访37.0个月,不联合同期顺铂组3年无失败生存率为88.3%,标准治疗组为87.6%,差异0.7%(单侧95%CI下限-3.9%;非劣效P=0.002);不联合同期顺铂组全级别呕吐发生率显著低于标准治疗组(26.2% vs 59.8%)。

要点

  • 不联合同期顺铂组3年无失败生存率88.3%,标准治疗组87.6%,达到非劣效(非劣效界值8%)。
  • 不联合同期顺铂组全级别呕吐发生率26.2%(68/260),标准治疗组59.8%(156/261),差异33.6%。
  • 不联合同期顺铂组患者报告的生活质量和耐受性更好,主要在胃肠道、功能和总体健康状况方面。

核心结论

  • 在局部晚期鼻咽癌患者中,特瑞普利单抗联合治疗不联合同期顺铂是一种可行的治疗,无失败生存疗效高且毒性低。

研究设计与样本

  • 开放标签、多中心、随机3期临床试验,2021年8月至2022年7月在中国13家医院纳入532例T4N1M0或T1-4N2-3M0鼻咽癌患者,400例(75.2%)按方案完成试验,末次随访日期为2025年3月21日。

主要发现

  • 意向治疗人群532例(中位[IQR]年龄47[39-54]岁;女性25.2%),中位随访37.0个月(范围4.0-50.0个月)。
  • 不联合同期顺铂组3年无失败生存率88.3%,标准治疗组87.6%,差异0.7%(单侧95%CI下限-3.9%;非劣效P=0.002;分层风险比0.92[95%CI 0.66-1.79];log-rank P=0.73)。
  • 安全性分析中,不联合同期顺铂组全级别呕吐发生率26.2%(68/260),标准治疗组59.8%(156/261),差异33.6%(单侧95%CI 26.9%-∞;P<0.001)。
  • 患者报告的生活质量(参与率87.5%)和耐受性(参与率94.7%)在不联合同期顺铂组更好,主要在胃肠道、功能和总体健康状况方面。

关键数值与推荐

  • 共主要终点为无失败生存(非劣效界值8%)和全级别呕吐发生率(优效性设计)。
  • 标准治疗组接受特瑞普利单抗联合吉西他滨-顺铂诱导化疗及同期顺铂放疗(100 mg/m2,每3周1次,共2周期)。
  • 不联合同期顺铂组接受相同方案但不含同期顺铂。
  • 特瑞普利单抗240 mg每3周1次共17周期,分布于诱导、放疗和辅助阶段分别为3、3和11周期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: With the programmed cell death protein 1 (PD-1) blockade toripalimab, omitting highly toxic concurrent cisplatin may be feasible for nasopharyngeal carcinoma (NPC) without compromising survival. OBJECTIVE: To evaluate the efficacy and safety of toripalimab incorporated into induction chemotherapy and radiotherapy, without concurrent cisplatin, for locoregionally advanced NPC. DESIGN, SETTING, AND PARTICIPANTS: Open-label, multicenter, randomized phase 3 clinical trial conducted from August 2021 to July 2022 at 13 hospitals in China, enrolling 532 patients with T4N1M0 or T1-4N2-3M0 NPC; 400 (75.2%) completed the trial per protocol. The final date of follow-up was March 21, 2025. INTERVENTIONS: Patients were randomly assigned to either the standard therapy group (n = 266), receiving toripalimab with gemcitabine-cisplatin induction chemotherapy and concurrent cisplatin-radiotherapy (100 mg/m2 triweekly for 2 cycles), or the concurrent cisplatin-sparing group (n = 266), receiving the same regimen without concurrent cisplatin. The 17 cycles of toripalimab (240 mg triweekly) were distributed across the induction, radiotherapy, and adjuvant phases as 3, 3, and 11 cycles, respectively. MAIN OUTCOMES AND MEASURES: Coprimary end points were failure-free survival (noninferiority margin, 8%) and incidence of all-grade vomiting (superiority design). Secondary end points included overall survival, locoregional recurrence-free survival, distant metastasis-free survival, safety, tumor response, quality of life, and tolerability. RESULTS: In the 532 patients in the intention-to-treat population (median [IQR] age, 47 [39-54] years; 25.2% women), after a median follow-up of 37.0 (range, 4.0-50.0) months, the concurrent cisplatin-sparing group had a 3-year failure-free survival rate of 88.3% vs 87.6% in the standard therapy group, a difference of 0.7% (lower limit of the 1-sided 95% CI, -3.9%; P = .002 for noninferiority; stratified hazard ratio, 0.92 [95% CI, 0.66-1.79]; log-rank P = .73). In the safety analysis, the incidence of all-grade vomiting was significantly lower in the concurrent cisplatin-sparing group vs the standard therapy group (26.2% [68/260] vs 59.8% [156/261]; difference, 33.6% [1-sided 95% CI, 26.9%-∞]; P < .001). Patient-reported quality of life (participation rate, 87.5%) and tolerability (participation rate, 94.7%) were better in the concurrent cisplatin-sparing group, primarily in gastrointestinal, functional, and global health status. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, among patients with locoregionally advanced NPC, toripalimab combination therapy without concurrent cisplatin was a feasible treatment with high efficacy in failure-free survival and low toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04907370.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Xu C, Liang XY, Huang XQ, et al. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. JAMA. 2025. PMID: 40839372. doi:10.1001/jama.2025.13205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。